Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc. Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass Period: August 3, 2023, through December 26, 2025Deadline to seek lead plaintiff status: April 6, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s drug, setrusumabInvestor action: Contact Kessler Topaz Meltzer & Check, LLP (www. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to alleged violations of federal securities laws related to misleading statements about the efficacy of its drug setrusumab for Osteogenesis Imperfecta [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Ultragenyx to contact them directly to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Ultragenyx [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives made false and misleading statements regarding the effects of setrusumab, creating a false impression of reliable information while downplaying risks associated with the Phase III Orbit study [4]. - Ultragenyx's optimism regarding the Phase III Orbit study's results was deemed misplaced, as the company failed to adequately disclose risks related to the study's Phase II results, which lacked a placebo control group [4]. Group 3: Stock Performance Impact - On July 9, 2025, Ultragenyx announced that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [5]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [6][7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6]. Group 2: Class Action Participation - Investors who purchased Mereo ADSs during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Ultragenyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 15, 2026 ...

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI), suggesting confidence in the drug's ability to reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which ultimately did not meet their primary endpoints [6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Core Viewpoint - Mereo BioPharma Group plc is facing potential legal claims due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and has set an April 6, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Mereo to contact them directly to discuss their legal options [1][8]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint failures, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [6].

Core Insights - Ultragenyx is accused of misleading investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The allegations suggest that Ultragenyx may have provided inaccurate information about the efficacy of setrusumab, which could impact investor confidence and stock performance [1]

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. SO WHAT: If you purchased Mereo ADSs during the Class Pe ...

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) (“Mereo” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Mereo American Depositary Shares (“ADS’s”) between June 5, 2023 and December 26, 2025, both dates inclusive (the "Class Period"). Investors have until April 6, 2026, to seek appointments as lead plaintiff. PLEASE ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of its drug setrusumab, impacting investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's ability to reduce fracture rates despite increasing bone density, which misled investors [5]. - Investors who purchased shares during the specified period may be eligible for compensation without incurring out-of-pocket costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].